Screener
Aclaris Therapeutics ACRS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
FAQ
- What is Aclaris Therapeutics's cash & equivalents?
- Aclaris Therapeutics (ACRS) reported cash & equivalents of $19.17M in Q2 2026.
- How has Aclaris Therapeutics's cash & equivalents changed year-over-year?
- Aclaris Therapeutics's cash & equivalents decreased by 24.5% year-over-year, from $25.4M to $19.17M.
- What is the long-term trend for Aclaris Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's cash & equivalents has grown at a -2.0% compound annual growth rate (CAGR), from $22.06M to $19.96M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Aclaris Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude